Form 4: BIO-TECHNE Director Amy Herr Reports Routine Stock Transactions
Insider Transaction Report
BIO-TECHNE Director Amy E. Herr disclosed routine transactions involving common stock and derivative securities, including RSU vesting and tax-related dispositions, executed under a 10b5-1 plan.
Summary
- Amy E. Herr, a Director of BIO-TECHNE Corp (TECH), reported transactions in common stock and derivative securities.
- Transactions occurred on February 3, 2026, and were made pursuant to a Rule 10b5-1(c) plan.
- 38 shares of common stock were acquired indirectly by a significant other at an exercise price of $0, resulting from the conversion of derivative securities (Restricted Stock Units).
- 16 shares of common stock were disposed of indirectly by a significant other at a price of $64.63, likely to cover tax liabilities related to the RSU vesting.
- Following these transactions, Amy E. Herr's direct beneficial ownership of common stock is 2,680 shares, and indirect beneficial ownership by a significant other is 2,176 shares.
- The filing also details various stock options and restricted stock units held directly and indirectly, with different vesting schedules and exercise prices.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine, pre-scheduled insider transactions (RSU vesting and tax-related sales) that do not indicate a change in company fundamentals or management's outlook.
Positives
- Transactions were executed under a Rule 10b5-1(c) plan, indicating pre-scheduled, non-discretionary trades, which can reduce concerns about opportunistic insider trading.
- Acquisition of shares at a $0 exercise price from RSU vesting represents a gain for the insider.
Negatives
- Disposition of 16 shares, even for tax purposes, reduces the insider's indirect holding.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider equity transactions.
Industry Context
StockSavvy.ai notes that routine insider transactions, particularly those executed under a Rule 10b5-1 plan, are common across industries. These transactions typically reflect pre-planned liquidity events or compensation structures rather than new strategic insights or reactions to market conditions. The biotech and life sciences sector, where BIO-TECHNE operates, often features equity-based compensation for directors and executives, making such filings a regular occurrence.
Comparison to Industry Standards
- StockSavvy.ai finds these transactions to be standard for executive compensation and tax planning within publicly traded companies.
- The use of a 10b5-1 plan aligns with best practices for corporate governance, demonstrating a commitment to transparency and mitigating concerns about opportunistic insider trading.
- No specific comparable companies or projects are detailed in this filing to allow for a direct comparison of results, as it focuses on individual equity movements rather than company performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compliance Practice | The transactions were executed under a Rule 10b5-1(c) plan, which is a standard corporate governance practice for managing insider trading compliance by allowing insiders to establish pre-arranged trading plans. | N/A | Enhances transparency and mitigates concerns about opportunistic insider trading, aligning with good governance principles. |
Related Party Transactions
- The filing discloses indirect beneficial ownership and derivative securities held 'By significant other,' which are standard related-party disclosures for beneficial ownership reporting under Section 16.
Stakeholder Impact
- Shareholders: The transactions are routine and pre-scheduled, unlikely to have a significant direct impact on existing shareholders beyond standard transparency of insider holdings.
- Employees: The vesting of RSUs and options is part of standard equity compensation, which can positively impact employee retention and alignment with company performance.
Next Steps
- The filing details future vesting dates for various stock options and restricted stock units, indicating ongoing equity compensation events for the reporting person and their significant other.
Key Dates
| Date | Description |
|---|---|
| 10/24/2025 | Date exercisable for a stock option with an exercise price of $72.05. |
| 10/30/2025 | Grant date for a stock option that vests on its one-year anniversary or the 2026 annual meeting. |
| 02/03/2026 | Transaction date for acquisition of 38 common shares and disposition of 16 common shares; also a vesting date for 38 restricted stock units and 86 stock options. |
| 02/05/2026 | Filing date of the Form 4. |
| 08/07/2026 | Expiration date for a fully vested stock option with an exercise price of $47.6. |
| 08/15/2026 | Vesting date for 118 restricted stock units, 160 restricted stock units, 311 restricted stock units, 524 stock options, 271 stock options, 367 stock options, and 912 stock options. |
| 02/03/2027 | Vesting date for 38 restricted stock units and 86 stock options. |
| 08/05/2027 | Expiration date for a fully vested stock option with an exercise price of $66.97. |
| 08/15/2027 | Vesting date for 160 restricted stock units, 311 restricted stock units, 271 stock options, 367 stock options, and 912 stock options. |
| 02/03/2028 | Vesting date for 39 restricted stock units and 86 stock options. |
| 08/06/2028 | Expiration date for a fully vested stock option with an exercise price of $120.46. |
| 08/15/2028 | Vesting date for 310 restricted stock units, 367 stock options, and 911 stock options. |
| 02/03/2029 | Vesting date for 86 stock options. |
| 08/15/2029 | Expiration date for a stock option with an exercise price of $94.52 (partially vested earlier). |
| 08/15/2030 | Expiration date for a stock option with an exercise price of $84.61 (partially vested earlier). |
| 08/15/2034 | Expiration date for a stock option with an exercise price of $74.91 (partially vested earlier). |
| 02/03/2035 | Expiration date for a stock option with an exercise price of $72.05 and another with an exercise price of $72.05. |
| 08/15/2035 | Expiration date for a stock option with an exercise price of $53.6. |
| 10/30/2035 | Expiration date for a stock option with an exercise price of $60.96. |
Recommendation
holdThis Form 4 filing reports routine, pre-scheduled insider transactions (RSU vesting and tax-related sales) by a director. These transactions are executed under a 10b5-1 plan and do not signal any new fundamental information about BIO-TECHNE's operational performance or strategic direction. Therefore, a seasoned investor would likely maintain their current position, as this filing provides no basis for a change in investment thesis.
Keywords
BIO-TECHNE, TECH, Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU, Beneficial Ownership, Director, Equity Transactions, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.